瑞舒伐他汀治疗高脂血症的效果和安全性
|
摘要
目的探讨瑞舒伐他汀治疗高脂血症的效果和安全性。方法选取2016年12月～2017年12月我院收治的46例高脂血症患者作为研究对象,按照随机数字表法分为A组(n=23)和B组(n=23)。A组给予对症治疗+辛伐他汀,B组给予对症治疗+瑞舒伐他汀,比较两组的治疗总有效率、用药前后总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平及不良反应发生情况。结果 B组用药后的临床总有效率(95.65%)显著高于A组(65.22%),差异有统计学意义(P<0.05)。两组用药后的TC、TG、LDL-C水平均低于用药前,HDL-C水平高于用药前,B组的TC、TG、LDL-C水平均低于A组,HDL-C水平高于A组,差异均有统计学意义(P<0.05);B组的不良反应总发生率(13.04%)显著低于A组(47.83%),差异有统计学意义(P<0.05)。结论瑞舒伐他汀对高脂血症患者具有较好的治疗效果,能显著改善患者的血脂代谢情况,降低胆固醇和低密度脂蛋白胆固醇水平,用药安全性较高。
Objective To explore the effect and safety of Rosuvastatin in the treatment of hyperlipidemia. Methods Forty-six patients with hyperlipidemia admitted to our hospital from December 2016 to December 2017 were selected as the study subjects, they were divided into group A(n=23) and group B(n=23) according to random number table method. Group A was given symptomatic treatment + Simvastatin, group B was given symptomatic treatment + Rosuvastatin, the total effective rate, total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C) and high density lipoprotein cholesterol(HDL-C) levels and adverse reactions before and after treatment were compared between the two groups. Results The total effective rate of group B(95.65%) was significantly higher than that of group A(65.22%), the difference was significant(P<0.05). The levels of TC, TG and LDL-C in the two groups after treatment were lower than those before treatment, the levels of HDL-C were higher than those before treatment, the levels of TC,TG and LDL-C in group B were lower than those in group A, the levels of HDL-C were higher than those in group A,the differences were statistically significant(P<0.05). The total incidence of adverse reactions in group B(13.04%) was significantly lower than that in group A(47.83%), the difference was statistically significant(P<0.05). Conclusion Rosuvastatin has a good therapeutic effect on hyperlipidemia patients, can significantly improve the blood lipid metabolism, reduce cholesterol and low density lipoprotein cholesterol levels, drug safety is high.
Objective To explore the effect and safety of Rosuvastatin in the treatment of hyperlipidemia. Methods Forty-six patients with hyperlipidemia admitted to our hospital from December 2016 to December 2017 were selected as the study subjects, they were divided into group A(n=23) and group B(n=23) according to random number table method. Group A was given symptomatic treatment + Simvastatin, group B was given symptomatic treatment + Rosuvastatin, the total effective rate, total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C) and high density lipoprotein cholesterol(HDL-C) levels and adverse reactions before and after treatment were compared between the two groups. Results The total effective rate of group B(95.65%) was significantly higher than that of group A(65.22%), the difference was significant(P<0.05). The levels of TC, TG and LDL-C in the two groups after treatment were lower than those before treatment, the levels of HDL-C were higher than those before treatment, the levels of TC,TG and LDL-C in group B were lower than those in group A, the levels of HDL-C were higher than those in group A,the differences were statistically significant(P<0.05). The total incidence of adverse reactions in group B(13.04%) was significantly lower than that in group A(47.83%), the difference was statistically significant(P<0.05). Conclusion Rosuvastatin has a good therapeutic effect on hyperlipidemia patients, can significantly improve the blood lipid metabolism, reduce cholesterol and low density lipoprotein cholesterol levels, drug safety is high.
引文
[1]赵洪君.瑞舒伐他汀和阿托伐他汀对冠心病伴高脂血症病人降脂效果的对比研究[J].中西医结合心脑血管病杂志,2016,14(6):622-624.
[2]徐芳,聂大庆,陈文莉,等.瑞舒伐他汀对改善维持性血液透析患者血脂和微炎症状态的研究[J].临床肾脏病杂志,2017,17(8):471-476.
[3]金巍,徐靖华,刘建光,等.瑞舒伐他汀钙对冠心病合并高脂血症患者血清hs-CRP及颈动脉内膜中层厚度的影响[J].现代生物医学进展,2016,16(23):4516-4519.
[4]李剑,闫双通,龚燕平,等.依折麦布联合瑞舒伐他汀治疗2型糖尿病合并高脂血症的临床效果[J].中国医药,2016,11(6):821-824.
[5]蒋丽,覃香,赖呈谋.瑞舒伐他汀与辛伐他汀治疗高脂血症临床疗效比较[J].海南医学,2017,28(9):1406-1408.
[6]刘建青,乔晋,王宏.阿托伐他汀、辛伐他汀和瑞舒伐他汀对高脂血症的疗效比较[J].药物评价研究,2017,40(10):1457-1459.
[7]刘少云,杨雪佳,孔立茶,等.瑞舒伐他汀与辛伐他汀治疗高脂血症有效性的Meta分析[J].天津医药,2017,45(12):1324-1329.
[8]王力泽.不同剂量辛伐他汀治疗高血压并高脂血症患者临床疗效及安全性的对比研究[J].实用心脑肺血管杂志,2017,25(1):67-69.
[9]谢妍.瑞舒伐他汀对冠心病患者血脂的干预作用[J].中国循证心血管医学杂志,2016,8(2):206-209.
[10]籍孟丽.不同他汀类药物(瑞舒伐他汀、辛伐他汀)对高龄患者高血脂改善效果的对比研究[J].临床检验杂志(电子版),2016,5(2):120-122.
[11]刁元彬,钱稚萍,罗江秀.瑞舒伐他汀治疗冠心病伴高脂血症的疗效及其对血脂、炎性介质及内皮指标的影响[J].疑难病杂志,2017,16(8):765-768.
[12]孙艳,田玉龙.瑞舒伐他汀与辛伐他汀在急性冠脉综合征患者中的应用效果研究[J].河北医药,2016,38(20):3167-3168.
[13]黄海燕,鄢卫民.4种他汀类药物治疗动脉粥样硬化的疗效和安全性比较[J].中国药房,2016,27(36):5100-5103.
[14]潘英丽.瑞舒伐他汀钙与辛伐他汀在高脂血症治疗中疗效及安全性对比[J].北方药学,2018,15(5):169-170.
[15]王鸫霖.瑞舒伐他汀与辛伐他汀在高脂血症患者中疗效及安全性对比[J].中国循证心血管医学杂志,2016,8(1):78-80.
[2]徐芳,聂大庆,陈文莉,等.瑞舒伐他汀对改善维持性血液透析患者血脂和微炎症状态的研究[J].临床肾脏病杂志,2017,17(8):471-476.
[3]金巍,徐靖华,刘建光,等.瑞舒伐他汀钙对冠心病合并高脂血症患者血清hs-CRP及颈动脉内膜中层厚度的影响[J].现代生物医学进展,2016,16(23):4516-4519.
[4]李剑,闫双通,龚燕平,等.依折麦布联合瑞舒伐他汀治疗2型糖尿病合并高脂血症的临床效果[J].中国医药,2016,11(6):821-824.
[5]蒋丽,覃香,赖呈谋.瑞舒伐他汀与辛伐他汀治疗高脂血症临床疗效比较[J].海南医学,2017,28(9):1406-1408.
[6]刘建青,乔晋,王宏.阿托伐他汀、辛伐他汀和瑞舒伐他汀对高脂血症的疗效比较[J].药物评价研究,2017,40(10):1457-1459.
[7]刘少云,杨雪佳,孔立茶,等.瑞舒伐他汀与辛伐他汀治疗高脂血症有效性的Meta分析[J].天津医药,2017,45(12):1324-1329.
[8]王力泽.不同剂量辛伐他汀治疗高血压并高脂血症患者临床疗效及安全性的对比研究[J].实用心脑肺血管杂志,2017,25(1):67-69.
[9]谢妍.瑞舒伐他汀对冠心病患者血脂的干预作用[J].中国循证心血管医学杂志,2016,8(2):206-209.
[10]籍孟丽.不同他汀类药物(瑞舒伐他汀、辛伐他汀)对高龄患者高血脂改善效果的对比研究[J].临床检验杂志(电子版),2016,5(2):120-122.
[11]刁元彬,钱稚萍,罗江秀.瑞舒伐他汀治疗冠心病伴高脂血症的疗效及其对血脂、炎性介质及内皮指标的影响[J].疑难病杂志,2017,16(8):765-768.
[12]孙艳,田玉龙.瑞舒伐他汀与辛伐他汀在急性冠脉综合征患者中的应用效果研究[J].河北医药,2016,38(20):3167-3168.
[13]黄海燕,鄢卫民.4种他汀类药物治疗动脉粥样硬化的疗效和安全性比较[J].中国药房,2016,27(36):5100-5103.
[14]潘英丽.瑞舒伐他汀钙与辛伐他汀在高脂血症治疗中疗效及安全性对比[J].北方药学,2018,15(5):169-170.
[15]王鸫霖.瑞舒伐他汀与辛伐他汀在高脂血症患者中疗效及安全性对比[J].中国循证心血管医学杂志,2016,8(1):78-80.